TY - JOUR
T1 - Chemotherapy of cervix cancer with doxorubicin and cisplatin
T2 - A phase I pilot study of the Gynecologic Oncology Group
AU - Omura, G. A.
AU - Hubbard, J.
AU - Hatch, K.
PY - 1985
Y1 - 1985
N2 - Twelve women with previously irradiated advanced pelvic cancer were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase 1 study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M2 and cisplatin 100 mg/M2 every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M2. Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.
AB - Twelve women with previously irradiated advanced pelvic cancer were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase 1 study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M2 and cisplatin 100 mg/M2 every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M2. Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.
UR - http://www.scopus.com/inward/record.url?scp=0022412683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022412683&partnerID=8YFLogxK
U2 - 10.1097/00000421-198510000-00001
DO - 10.1097/00000421-198510000-00001
M3 - Article
C2 - 4061371
AN - SCOPUS:0022412683
SN - 0277-3732
VL - 8
SP - 347
EP - 349
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 5
ER -